PCV13: Effective Against First-Episode CAP in Older Adults

ACOG CEO: “In the face of misinformation and vaccine hesitancy, a strong, evidence-based recommendation...from a trusted clinician can go a long way."

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

The US FDA approved brensocatib as the first treatment for non–cystic fibrosis bronchiectasis.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Apnimed's first-in-class anti-apneic AD109 increases upper airway muscle tone during sleep; the company plans to file an NDA with the FDA in early 2026.

Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.